Clinical trial
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
NCT05974410
Study timeline
Registry last updated2025-10-02
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Glioblastomaunresolved
Squamous Cell Carcinomaunresolved
Hodgkin Lymphomaunresolved
Non-hodgkin Lymphomaunresolved
Breast Cancerunresolved
Prostate Cancerunresolved
Gastric Cancerunresolved
Ovarian Cancerunresolved
Acute Leukemiaunresolved
Pancreatic Cancerunresolved
Spindle Cell Sarcomaunresolved
Cancerunresolved
Tumor, Solidunresolved
Tumor, Brainunresolved
Esophageal Andeocarcinomaunresolved
Mixed Phenotype AMLunresolved
Desmoplastic Round Cell Sarcomaunresolved
Interventions
Sponsors & collaborators
AVM Biotechnology Inclead sponsor
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05974410 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.